Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 13 of 13 entries
View as:

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04156269 Org: User:
Start: 08/31/18 End: 09/01/21 Due: 09/01/22

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04156178 Org: User:
Start: 08/01/18 End: 09/30/20 Due: 09/30/21

CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04156256 Org: User:
Start: 03/01/18 End: 09/30/20 Due: 09/30/21

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05445765 Org: User:
Start: 07/01/22 End: 06/30/24 Due: 06/30/25

BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Phase: N/A Priority: Normal
NCT ID: NCT05474885 Org: User:
Start: 04/01/22 End: 04/30/25 Due: 04/30/26

CD4-specific CAR T Cells (CD4 CAR T Cells) for Relapsed/Refractory T Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04162340 Org: User:
Start: 07/11/19 End: 10/31/21 Due: 10/31/22

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05212584 Org: User:
Start: 07/01/22 End: 06/30/24 Due: 06/30/25

BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06787989 Org: User:
Start: 08/31/24 End: 04/30/27 Due: 04/30/28

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04156243 Org: User:
Start: 02/01/18 End: 02/28/20 Due: 02/28/21

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

Phase: N/A Priority: Normal
NCT ID: NCT04934774 Org: User:
Start: 12/01/20 End: 06/01/23 Due: 06/01/24

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03795779 Org: User:
Start: 03/01/18 End: 09/30/22 Due: 09/30/23

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04162353 Org: User:
Start: 05/31/21 End: 09/30/21 Due: 09/30/22

Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04594135 Org: User:
Start: 12/01/20 End: 11/30/23 Due: 11/30/24